Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates.

Adeno-associated viral (AAV) vectors have become the primary delivery agent for somatic gene transfer into the central nervous system (CNS). To date, AAV-mediated gene delivery to the CNS is based on serotypes 1-9, with efficient gene transfer to neurons only-selective and widespread transduction of glial cells have not been observed. Recently, additional endogenous AAVs have been isolated from nonhuman primate tissues. In this study, transduction obtained with AAV serotypes bb2, cy5, rh20, rh39, and rh43 was compared to that obtained with AAV8, another nonhuman primate isolate previously shown to perform well in mammalian brain. Titer-matched vectors encoding the enhanced green fluorescent protein (EGFP) reporter, driven by the constitutive CAG promoter, were injected into the hippocampus, striatum, or substantia nigra (SN) of adult rats. More widespread neuronal transduction was observed following infusion of cy5, rh20, and rh39 than observed with AAV8. Of interest, preferential transduction of astrocytes was observed with rh43. To optimize glial transduction, vector stocks driven by cell-specific promoters were generated-widespread and targeted transduction of astrocytes and oligodendrocytes was observed using rh43 and AAV8, driven by the glial fibrillary acidic protein (GFAP) and myelin basic protein (MBP) promoters, expanding the utility of AAV for modeling and treating diseases involving glial cell pathology.

[1]  Y. Chan,et al.  Reactive astrocytes as potential manipulation targets in novel cell replacement therapy of Parkinson's disease. , 2005, Current drug targets.

[2]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[3]  R. Kotin,et al.  Recombinant adeno-associated virus serotypes 2- and 5-mediated gene transfer in the mammalian brain: quantitative analysis of heparin co-infusion. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  R. Mandel,et al.  Clinical trials in neurological disorders using AAV vectors: promises and challenges. , 2004, Current opinion in molecular therapeutics.

[5]  T. McCown.  Adeno-Associated Virus (AAV) Vectors in the CNS. , 2005, Current gene therapy.

[6]  R. Samulski,et al.  Selective and rapid uptake of adeno-associated virus type 2 in brain. , 1998, Human gene therapy.

[7]  David Eidelberg,et al.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial , 2007, The Lancet.

[8]  R. Samulski,et al.  Adeno-associated virus serotypes: vector toolkit for human gene therapy. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  J. Brotchi,et al.  Recombinant AAV‐mediated gene delivery to the central nervous system , 2004, The journal of gene medicine.

[10]  J. Wolfe,et al.  Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  Ren-zhi Wang,et al.  Intra-ventricular infusion of rAAV1-EGFP resulted in transduction in multiple regions of adult rat brain: A comparative study with rAAV2 and rAAV5 vectors , 2006, Brain Research.

[12]  I. Martins,et al.  Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS , 2005, Gene Therapy.

[13]  E. Giacobini,et al.  One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? , 2007, Journal of Alzheimer's disease : JAD.

[14]  R. Mandel,et al.  Circulating Anti-Wild-Type Adeno-Associated Virus Type 2 (AAV2) Antibodies Inhibit Recombinant AAV2 (rAAV2)-Mediated, but Not rAAV5-Mediated, Gene Transfer in the Brain , 2004, Journal of Virology.

[15]  P. Worley,et al.  Homer2 Is Necessary for EtOH-Induced Neuroplasticity , 2005, The Journal of Neuroscience.

[16]  B. Hyman,et al.  Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain , 2006, Neuroscience.

[17]  K. Jooss,et al.  Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors. , 2006, Human gene therapy.

[18]  Zeger Debyser,et al.  Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. , 2007, Human gene therapy.

[19]  David V. Schaffer,et al.  Designer Gene Delivery Vectors: Molecular Engineering and Evolution of Adeno-Associated Viral Vectors for Enhanced Gene Transfer , 2007, Pharmaceutical Research.

[20]  W. Banks,et al.  Glucagon-like peptide-1 receptor is involved in learning and neuroprotection , 2003, Nature Medicine.

[21]  M. Nilsson,et al.  Astrocyte activation and reactive gliosis , 2005, Glia.

[22]  P. Pivirotto,et al.  Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  K. Foust,et al.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes , 2009, Nature Biotechnology.

[24]  M. R. Delgado Alvira,et al.  Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues , 2004, Journal of Virology.

[25]  M. Dragunow,et al.  Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes , 2001, Gene Therapy.

[26]  James M. Wilson,et al.  New recombinant serotypes of AAV vectors. , 2005, Current gene therapy.

[27]  R. Klein,et al.  AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  Hong Yu Chen,et al.  Oligodendrocyte‐specific gene expression in mouse brain: Use of a myelin‐forming cell type–specific promoter in an adeno‐associated virus , 1999, Journal of neuroscience research.

[29]  Yun Wang,et al.  Tropism and toxicity of adeno-associated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia in vitro. , 2008, Virology.

[30]  J. Rothstein,et al.  Mechanisms of Disease: astrocytes in neurodegenerative disease , 2006, Nature Clinical Practice Neurology.

[31]  K. G. Rajeev,et al.  Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits , 2007, Proceedings of the National Academy of Sciences.

[32]  R. Mandel,et al.  Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  James M. Wilson,et al.  Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  Ronald L Klein,et al.  Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  R. Mandel,et al.  Systemic mannitol-induced hyperosmolality amplifies rAAV2-mediated striatal transduction to a greater extent than local co-infusion. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  P. Reier,et al.  Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  T. Golde,et al.  Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Aβ levels , 2007, Molecular Neurodegeneration.

[38]  M. Klugmann,et al.  Development and optimization of adeno-associated virus vector transfer into the central nervous system. , 2003, Methods in molecular medicine.

[39]  H. Chen,et al.  Gene transfer and expression in oligodendrocytes under the control of myelin basic protein transcriptional control region mediated by adeno-associated virus , 1998, Gene Therapy.

[40]  M. During,et al.  Somatic gene transfer of cAMP response element-binding protein attenuates memory impairment in aging rats. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Kügler,et al.  Promoters and serotypes: targeting of adeno‐associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo , 2005, Experimental physiology.

[42]  M. During,et al.  Combined injection of rAAV with mannitol enhances gene expression in the rat brain. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  T. Serikawa,et al.  Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.